Compare Enveric Biosciences Inc (ENVB) vs Expensify Inc (EXFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Expensify Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Expensify Inc trades at $2.3 (market cap $206.99M). The key difference: Expensify Inc is far larger — about 30.9× Enveric Biosciences Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Expensify Inc for 41 Days on average.
| ENVB | EXFY | |
|---|---|---|
Market Cap | $6.69M | $206.99M |
Volume | 41,141 | 256,089 |
Sector | Health | Technology |
52-Week High | $10.80 | $2.72 |
52-Week Low | $1.27 | $0.75 |
Typical Hold Time | 14 Days | 41 Days |
Enterprise Value | -$1.60M | $146.61M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Expensify (EXFY) trades at $2.27, up 1.79% on the day, with a neutral technical signal and bullish moving averages. The company reported Q2 2026 earnings of $0.04 per share, beating estimates, and raised free cash flow guidance. Revenue trends show stabilization around $140M annually, though net income remains negative. Recent news highlights AI-native ERP integrations and European card expansion, signaling growth initiatives.
The outlook is mixed: analyst consensus is bullish with a $13.75 price target, but high P/E of 258.82 and persistent losses pose valuation risks. Investment opportunity lies in execution of AI-driven products and cash flow improvement, while key risks include competitive pressure and failure to achieve sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →
